PAHC250117P25000
- 0.00
- 0.000.00%
Phibro Animal Health Newsroom
Phibro Animal Health Is Maintained at Equal-Weight by Morgan Stanley
Phibro Animal Health Analyst Ratings
Morgan Stanley Maintains Phibro Animal Health(PAHC.US) With Hold Rating, Raises Target Price to $25
Phibro Animal Health Is Maintained at Underweight by Barclays
Barclays Maintains Phibro Animal Health(PAHC.US) With Sell Rating, Raises Target Price to $20
Barclays Sticks to Their Sell Rating for Phibro Animal Health (PAHC)
Barclays Maintains Phibro Animal Health(PAHC.US) With Sell Rating, Maintains Target Price $13
Barclays Remains a Sell on Phibro Animal Health (PAHC)
Phibro Animal Health Initiated at Neutral by JP Morgan
Phibro Animal Health Analyst Ratings
J.P. Morgan Initiates Phibro Animal Health(PAHC.US) With Hold Rating, Announces Target Price $22
Phibro Animal Health Is Maintained at Underperform by B of A Securities
Phibro Animal Health Analyst Ratings
BofA Securities Maintains Phibro Animal Health(PAHC.US) With Sell Rating, Raises Target Price to $15
Barclays Maintains Phibro Animal Health(PAHC.US) With Sell Rating, Maintains Target Price $13
Phibro Animal Health (PAHC) Receives a Sell From Barclays
BofA Securities Maintains Phibro Animal Health(PAHC.US) With Sell Rating, Raises Target Price to $13
Phibro Animal Health Sell Rating: Concerns Over Operating Leverage and Profitability Despite Revenue Growth
Analysts Offer Insights on Healthcare Companies: Phibro Animal Health (PAHC) and Veeva Systems (VEEV)
Phibro Animal Health Analyst Ratings